Isifundo esitsha siJolise phakathi ukuya kwiOsteoarthritis eMandundu yeDolo

I-Ageless Biotech, Inc. I-Sheridan, i-WY inkampani ye-biotech eyenzelwe ukuzisa unyango olusekelwe kwi-stem cell-based to market, ifumene i-US Food and Drug Administration (FDA) yoPhando lweSicelo esitsha seChiza (IND) sonyango lwe-Osteoarthritis yedolo.              

I-Arthritis Foundation ichaze iOsteoarthritis "njengesifo esingapheliyo ... esinganyangekiyo." Kwiminyaka elishumi edlulileyo kwi-2009 ABC News yapapashwa, unyango lwezigulane ze-osteoarthritis e-United States zixabisa i-185.5 yeebhiliyoni zeedola ngonyaka.

Kwiminyaka nje ye-4 emfutshane, ukusuka kwi-2009 Arthritis Foundation ingxelo iindleko ze-OA e-USA ziphindwe kabini njengoko zipapashwe kwi-2013 yingxelo ye-CDC yokuba iindleko ze-Osteoarthritis zonyaka "zaziyi-303.5 yeebhiliyoni zeedola okanye i-1% ye-2013 US Gross Domestic Product (GDP) .”  

UMongameli we-Ageless Biotech, Inc, uVince Liguori ubonisa, "ukufunyanwa kweNqanaba le-II ye-OA ye-Knee Clinical Trial ivumela ukuba siqale iimvavanyo ngokukhawuleza ngezicwangciso zokuqalisa ekupheleni kuka-Matshi 2022. Le FDA yamkelwe i-IND ivumela i-Ageless I-Biotech ukuzisa imveliso ye-Osteoarthritis Stem Cell kubo bobabini ooGqirha nakwiZigulana ngokukhawuleza. ”

I-Ageless Biotech IND isebenzisa iiseli ze-Adipose Derived Stem Cells ngaphandle kwe-enzymes okanye ezinye iikhemikhali ngokusebenzisa inkqubo yobunikazi yendlela eyaziwayo ebizwa ngokuba yi-Stromal Vascular Fraction (SVF) eyenza i-matrix yeeseli zomntu eziphilayo. I-Ageless Biotech iceba ukungqina iipropathi ezivuselelayo zeMveliso ye-Ageless Biotech SVF ngaphambi kokuphela kwesi sifundo seklinikhi esamkelweyo se-FDA ngelixa kwangaxeshanye sibonisa ukhuseleko kunye nexesha elisezantsi lesigulane. I-Ageless Biotech ikholelwa ukuba izigidi zotyando lwamadolo lonyaka luya kutshintshwa ngesitofu esilula samadolo. Ngelixa sikholelwa ukuba obu buchwephesha ekugqibeleni buza kunikwa ilayisenisi koogqirha ukuze basasazwe ngobuninzi, sijonga ngokushushu “ngaphandle kweshelufu” Iinketho zokuthobela uhlobo lwe-HLA ukuncoma unyango olunjalo kwikamva “elingekude kangako”.

UMlawuli weNtengiso we-BioXstem kaZwelonke, kunye neLungu leBhodi ye-Ageless Biotech uJon Youngs uyibeka ngcono ngokuthi, “Thina kwa-BioXstem sonwabe kakhulu ukuba ngumtyali-mali osebenzayo we-Ageless Biotech kuba ngoku asithethi ngayo nje. Sinokuthi ngenene sithatha inxaxheba kwi-FDA IND kunye nenxalenye yobunkokeli obuqhubela phambili iyeza. ”